No Data
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
UBS Initiates Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $37
Kura Downgraded to Hold by Stifel, Prefers Rival Syndax
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Analyst Ratings